Effect of hyperglycemic condition on proteoglycan secretion in cultured human endothelial cells

European Journal of Nutrition

Volumn 45, Issue 7, 2006, Pages 369-375

  Gharagozlian, Sedegheh ^a,b   Borrebæk, Jørgen ^a   Henriksen, Tore ^c   Omsland, Tone Kristin ^a   Shegarfi, Hamid ^a   Kolset, Svein Olav ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diabetes; Endothelial cells; Hyperglycemia; Proteoglycans

Indexed keywords

CHONDROITIN; GLUCOSE; GLYCOSAMINOGLYCAN; PROTEOGLYCAN;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROPHORESIS; ENDOTHELIUM CELL; GEL CHROMATOGRAPHY; GEL FILTRATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOPRECIPITATION; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOGLYCAN SYNTHESIS;

BASEMENT MEMBRANE; CELL MEMBRANE; CELLS, CULTURED; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; HYPERGLYCEMIA; IMMUNOPRECIPITATION; MOLECULAR WEIGHT; PROTEOGLYCANS; SULFUR RADIOISOTOPES; UMBILICAL CORD;

EID: 33750365586     PISSN: 14366207     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00394-006-0608-9     Document Type: Article

References (28)

1. The Diabetes Control, Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
2. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm 11(18):2279-2299
3. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
4. Selleck SB (2000) Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet 16(5):206-212
5. Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60:443-475
6. Kolset SO, Salmivirta M (1999) Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cell Mol Life Sci 56:857-870
7. Miner JH (1999) Renal basement membrane components. Kidney Int 56:2016-2024
8. Saku T, Furthmayr H (1989) Characterization of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. Homology to the large molecular weight molecule of basement membranes. J Biol Chem 264:3514-3523
9. Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67:609-652
10. Rops AL, van der Vlag J, Lensen JF, et al. (2004) Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65:768-785
11. Wang L, Fuster M, Sriramarao P, Esko JD (2005) Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6:902-910
12. Bollineni JS, Alluru I, Reddi AS (1997) Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 16:127-130
13. Laffont I, Shuvaev VV, Briand O, et al. (2002) Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochim Biophys Acta 1583:99-107
14. Vogl-Willis CA, Edwards IJ (2004) High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672:36-45
15. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219-226
16. Jensen T (1997) Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 46(Suppl 2):S98-S100
17. Kjellen L, Bielefeld D, Hook M (1983) Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32:337-342
18. Ha TS, Song CJ, Lee JH (2004) Effects of advanced glycosylation endproducts on perlecan core protein of glomerular epithelium. Pediatr Nephrol 19:1219-1224
19. Vogl-Willis CA, Edwards IJ (2004) High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 24:858-863
20. Shively JE, Conrad HE (1976) Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry (Mosc) 15:3932-3942
21. Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ (1991) Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 266:23274-23281
22. Edwards IJ, Wagner JD, Vogl-Willis CA, Litwak KN, Cefalu WT (2004) Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 3:6
23. Nugent MA, Iozzo RV (2000) Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115-120
24. Garin EH, Shirey AJ (1988) Glomerular basement membrane heparan sulfate glycosaminoglycan in aminonucleoside of puromycin nephrosis. Child Nephrol Urol 9:121-126
25. Sorensson J, Bjornson A, Ohlson M, Ballermann BJ, Haraldsson B (2003) Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol Renal Physiol 284:F373-F380
26. Borrebæk J, Prydz K, Fjeldstad K, et al. (2001) The AGE product N epsilon-(carboxymethyl)lysine serum albumin is a modulator of proteoglycan expression in polarized cultured kidney epithelial cells. Diabetologia 44:488-494
27. Osawa T, Kato Y (2005) Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann NY Acad Sci 1043:440-451
28. Way KJ, Isshiki K, Suzuma K, et al. (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51:2709-2718